Murugesan Gounder

1.2k total citations
36 papers, 962 citations indexed

About

Murugesan Gounder is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Murugesan Gounder has authored 36 papers receiving a total of 962 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 18 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Murugesan Gounder's work include Cancer therapeutics and mechanisms (9 papers), Cancer-related Molecular Pathways (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Murugesan Gounder is often cited by papers focused on Cancer therapeutics and mechanisms (9 papers), Cancer-related Molecular Pathways (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Murugesan Gounder collaborates with scholars based in United States, Germany and Japan. Murugesan Gounder's co-authors include Dmitri Dvorzhinski, Hongxia Lin, Eric H. Rubin, Mark N. Stein, Robert S. DiPaola, Susan Goodin, Eileen White, Joseph R. Bertino, Kevin Bray and Chandrika Jeyamohan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Molecular and Cellular Biology.

In The Last Decade

Murugesan Gounder

36 papers receiving 949 citations

Peers

Countries citing papers authored by Murugesan Gounder

Since Specialization

Citations

This map shows the geographic impact of Murugesan Gounder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Murugesan Gounder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Murugesan Gounder more than expected).

Fields of papers citing papers by Murugesan Gounder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Murugesan Gounder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Murugesan Gounder. The network helps show where Murugesan Gounder may publish in the future.

Co-authorship network of co-authors of Murugesan Gounder

This figure shows the co-authorship network connecting the top 25 collaborators of Murugesan Gounder. A scholar is included among the top collaborators of Murugesan Gounder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Murugesan Gounder. Murugesan Gounder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	67MO Long-term nirogacestat treatment in adult patients with desmoid tumors: Updated efficacy and safety from the phase III DeFi trial 2025 ·ESMO Open ·(unknown), (unknown), (unknown), Winette T.A. van der Graaf, (unknown), Nam Bui, Gina Z. D’Amato, (unknown), Steven Attia, (unknown), Yu‐De Chu, Robert Cohen, Ana B. Oton, (unknown), (unknown), Murugesan Gounder	1
2	56O A phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828): Safety and efficacy in patients with dedifferentiated liposarcoma 2024 ·ESMO Open ·Patrick Schöffski, Patricia LoRusso, Nobuyuki Yamamoto, Peter Reichardt, Lawrence H. Schwartz, Laurent Dercle, B. Zhao, Rhea Chitalia, Grant W. Montgomery, Chen Hu, (unknown), (unknown), Murugesan Gounder	3
3	A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850 2023 ·Oncotarget ·Kristen Spencer, (unknown), Joseph Aisner, Mark N. Stein, Jyoti Malhotra, Weichung Shih, Nancy Chan, Ann W. Silk, Shridar Ganesan, Susan Goodin, Murugesan Gounder, Hongxia Lin, Jiadong Li, (unknown), (unknown), Suzie Chen, Janice M. Mehnert	5
4	1548P A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma 2021 ·Annals of Oncology ·Murugesan Gounder, Munjal Patel, Nobuyuki Yamamoto, Todd M. Bauer, Scott A. Laurie, (unknown), Jia Geng, Joyce Cheng, (unknown), Patricia LoRusso	1
5	A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies 2021 ·Cancer Chemotherapy and Pharmacology ·Antoinette R. Tan, Nancy Chan, Brian F. Kiesel, Mark N. Stein, Rebecca A. Moss, Jyoti Malhotra, Joseph Aisner, Mansi Shah, Murugesan Gounder, Hongxia Lin, Michael P. Kane, Yong Lin, Jiuping Ji, Alice P. Chen, Jan H. Beumer, Janice M. Mehnert	2
6	Phase I trial of selenium plus chemotherapy in gynecologic cancers 2018 ·Gynecologic Oncology ·(unknown), (unknown), Murugesan Gounder, Darlene Gibbon, Wilberto Nieves‐Neira, Ami Vaidya, Mira Hellmann, Michael P. Kane, Brian Buckley, Weichung Joe Shih, Paula B. Caffrey, G Frenkel, Lorna Rodríguez-Rodríguez	28
7	Pharmacokinetics and pharmacodynamics of 3,3′-diindolylmethane (DIM) in regulating gene expression of phase II drug metabolizing enzymes 2015 ·Journal of Pharmacokinetics and Pharmacodynamics ·Tien‐Yuan Wu, Ying Huang, Chengyue Zhang, Zheng‐Yuan Su, Sarandeep S. S. Boyanapalli, Tin Oo Khor, Hu Wang, Hongxia Lin, Murugesan Gounder, Leonid Kagan, Ioannis P. Androulakis, Ah‐Ng Tony Kong	13
8	A sensitive liquid chromatography–mass spectrometry bioanalytical assay for a novel anticancer candidate – ZMC1 2015 ·Biomedical Chromatography ·Hongxia Lin, Xin Yu, Oliver S. Eng, Brian Buckley, Ah‐Ng Tony Kong, Joseph R. Bertino, Darren R. Carpizo, Murugesan Gounder	4
9	Suppression of Cytosolic NADPH Pool by Thionicotinamide Increases Oxidative Stress and Synergizes with Chemotherapy 2015 ·Molecular Pharmacology ·Philip M. Tedeschi, Hongxia Lin, Murugesan Gounder, John E. Kerrigan, Emine Ercikan Abali, Kathleen W. Scotto, Joseph R. Bertino	35
10	Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells 2013 ·Cell Death and Disease ·Philip M. Tedeschi, Elke Markert, Murugesan Gounder, Huan Lin, Dmitri Dvorzhinski, Sonia Dolfi, (unknown), (unknown), Robert S. DiPaola, Kim M. Hirshfield, László G. Boros, Joseph R. Bertino, Zoltán N. Oltvai, Alexei Vázquez	207
11	E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer 2013 ·Cancer Chemotherapy and Pharmacology ·Taofeek K. Owonikoko, Joseph Aisner, Victoria Wang, Suzanne E. Dahlberg, Eric H. Rubin, Suresh S. Ramalingam, Murugesan Gounder, (unknown), Rita Axelrod, Joan H. Schiller	3
12	A validated HPLC assay for the determination of R-(−)-gossypol in human plasma and its application in clinical pharmacokinetic studies 2012 ·Journal of Pharmaceutical and Biomedical Analysis ·Hongxia Lin, Murugesan Gounder, Joseph R. Bertino, Ah‐Ng Tony Kong, Robert S. DiPaola, Mark N. Stein	9
13	Deficiency of the dual ubiquitin/SUMO ligase Topors results in genetic instability and an increased rate of malignancy in mice 2010 ·BMC Molecular Biology ·(unknown), Mantu Bhaumik, Hana Aviv, Dirk F. Moore, Ming Yao, Jayeeta Dutta, Hussein Rahim, Murugesan Gounder, Shridar Ganesan, Ahamed Saleem, Eric H. Rubin	21
14	Targeting tumor metabolism with 2‐deoxyglucose in patients with castrate‐resistant prostate cancer and advanced malignancies 2010 ·The Prostate ·Mark N. Stein, Hongxia Lin, Chandrika Jeyamohan, Dmitri Dvorzhinski, Murugesan Gounder, Kevin Bray, Simantini Eddy, Susan Goodin, Eileen White, Robert S. DiPaola	238
15	Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia 2008 ·Anti-Cancer Drugs ·Biren Saraiya, Murugesan Gounder, Jayeeta Dutta, Ahamed Saleem, (unknown), (unknown), (unknown), Mecide Gharibo, Dale Schaar, Yong Lin, Weichung Shih, Joseph Aisner, Roger Strair, Eric H. Rubin	16
16	Optimal modeling for phase I design of a two drug combination—results of a phase I study of cisplatin with 9-nitrocamptothecin 2008 ·Investigational New Drugs ·(unknown), Murugesan Gounder, Eric H. Rubin, (unknown), Zhe-ming Gu, (unknown), (unknown), Andrzej P. Kudelka, Claire F. Verschraegen	4
17	A study of the interactions between carboplatin and blood plasma proteins using size exclusion chromatography coupled to inductively coupled plasma mass spectrometry 2007 ·Analytical and Bioanalytical Chemistry ·(unknown), Willie Johnson, Lorna Rodriguez, Murugesan Gounder, Gene S. Hall, Brian Buckley	47
18	Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan 2007 ·Investigational New Drugs ·Murugesan Gounder, (unknown), Ahamed Saleem, Pooja Pungaliya, Diptee Kulkarni, Richard Versace, Eric H. Rubin	18
19	A phase I and pharmacokinetic study of paclitaxel and carboplatin combined with sodium selenite in patients with gynecologic malignacies 2005 ·Cancer Research ·Murugesan Gounder, Darlene Gibbon, (unknown), (unknown), Brian Buckley, (unknown), Yong Lin, Weichung Joe Shih, G Frenkel, Paula B. Caffrey, Eric H. Rubin, (unknown)	1
20	Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. 2003 ·PubMed ·(unknown), Murugesan Gounder, Ahamed Saleem, Jan H.M. Schellens, Douglas D. Ross, Susan E. Bates, Patrick J. Sinko, Eric H. Rubin	54

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact